Azitra Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company focused on precision dermatology. Recent disclosures cover proxy materials for annual and special stockholder meetings, shareholder voting procedures, board and governance matters, and meeting-status updates filed on Form 8-K.
Azitra's SEC reports also describe material agreements and capital-structure changes, including private placement securities, Series A preferred stock and Series B and Series C warrants. Other filings address furnished financial results, pipeline business updates, use of financing proceeds for research and development and working capital, and NYSE American continued-listing compliance matters tied to stockholders' equity standards.
Azitra, Inc. reported that President and CEO Francisco D. Salva received a grant of stock options covering 220,879 shares of common stock. The options have an exercise price of $0.2127 per share and expire on April 20, 2036.
According to the vesting terms, one-third of the options vest on the one-year anniversary of the grant date, and the remaining two-thirds vest in equal monthly installments over the following two years. After this grant, Salva directly holds options for 220,879 underlying shares.
Azitra, Inc. reported that Chief Operating Officer Travis Whitfill received a grant of stock options covering 64,300 shares of common stock. The options carry an exercise price of $0.2127 per share and expire on April 20, 2036.
According to the vesting terms, one-third of the options will vest on the one-year anniversary of the grant date, and the remaining two-thirds will vest in equal monthly installments over the following two years. After this grant, Whitfill holds 64,300 stock options directly.
Azitra, Inc. has completed a private PIPE financing that can provide up to approximately $31.4 million, including initial gross proceeds of about $10.5 million from the sale of 10,485 shares of Series A convertible non-redeemable preferred stock bundled with warrants.
Each preferred share is paired with Series B and Series C warrants, each initially exercisable at $0.123 per share. After stockholder approval of additional authorized common shares and the related NYSE American requirements, each preferred share will automatically convert into roughly 8,128.1 common shares, subject to beneficial ownership caps of 4.99%, 9.99% or 19.99% per holder, with excess delivered as pre-funded warrants.
The Series B warrants become exercisable after stockholder approval and terminate 18 months later, while Series C warrants remain exercisable until 30 days after Azitra publicly reports data from its cosmetic filaggrin human study, with a potential 30-day extension and exercise price reset if the stock trades below the original strike. A registration rights agreement requires Azitra to file a resale registration statement within 45 days of closing, with liquidated damages of 1% of each investor’s purchase amount per 30 days if key registration milestones are missed. Azitra plans to use the initial net proceeds, together with existing cash, for research and development, general corporate purposes and working capital.
Azitra, Inc. President and CEO Francisco D. Salva reported significant insider purchases of derivative securities. On March 18, 2026, he bought 500 shares of Series A Convertible Non-Redeemable Preferred Stock, which has a stated value of $1,000 per share and automatically converts into 8,128.1 shares of common stock per preferred share once specific stockholder approvals and a charter amendment are obtained.
He also purchased 4,064,050 Series B Warrants and 4,064,050 Series C Warrants, each exercisable for common stock at $0.123 per share. The Series B Warrants become exercisable upon stockholder approval and expire 18 months afterward, while the Series C Warrants become exercisable upon stockholder approval and terminate 30 days after Azitra publicly announces data from its planned human cosmetic study using filaggrin technology.
Azitra, Inc. received a notice from NYSE American that it is not in compliance with the exchange’s continued listing standard requiring stockholders’ equity of at least $6.0 million for companies with losses in their five most recent fiscal years. As of December 31, 2025, Azitra reported stockholders’ equity of $3.8 million and losses over that five-year period. The exchange has accepted a previously submitted plan giving Azitra until April 1, 2027 to regain compliance with both the $4.0 million and $6.0 million equity thresholds, during which the company must provide quarterly progress updates. If it fails to make sufficient progress or meet these standards by the deadline, NYSE American staff may initiate delisting proceedings, though Azitra could appeal. The company also highlights that its latest audited financial statements contain an auditor’s paragraph expressing substantial doubt about its ability to continue as a going concern. Trading of Azitra’s common stock continues on NYSE American for now.
Azitra, Inc. canceled its 2026 special meeting of stockholders. The meeting was originally scheduled for February 6, 2026 and adjourned to March 6, 2026 after the company previously lacked a quorum. On March 4, 2026, Azitra withdrew the proposals described in its definitive proxy statement and decided not to reconvene the adjourned meeting.
Azitra is a clinical stage biopharmaceutical company focused on precision dermatology. Its lead program, ATR-12, is an engineered strain of S. epidermidis for Netherton syndrome and includes a Phase 1b trial in adult patients. A second program, ATR-04, targets EGFR inhibitor–associated rash and has FDA Fast Track designation and an open IND.
Azitra, Inc. reported full-year 2025 results and highlighted progress across its dermatology pipeline. For the year ended December 31, 2025, the company generated no revenue versus $7,500 in 2024 and recorded a net loss of $10.96M, wider than $8.97M a year earlier.
Research and development expenses were $4.8M and general and administrative expenses were $6.1M, both roughly flat year over year. Cash and cash equivalents were $2.07M at December 31, 2025, down from $4.55M at the prior year-end, after completing $8.5M of financings during 2025.
Clinically, Azitra advanced ATR-12, its lead program for Netherton syndrome, reporting promising Phase 1b safety data and guiding to topline results in the second half of 2026. ATR-04 for EGFR inhibitor–associated rash dosed its first Phase 1/2 patient, with initial cohort data expected around mid-2026, while ATR-01 for ichthyosis vulgaris reported positive preclinical data and continues IND-enabling work into 2026.
Azitra, Inc. files its annual report describing an early-stage biopharmaceutical business focused on precision dermatology using engineered proteins and topical live biotherapeutic products. The company has built a proprietary microbial library of about 1,500 bacterial strains supported by artificial intelligence and licensed genetic engineering technology.
Its lead programs are ATR-12 for Netherton syndrome, ATR-04 for epidermal growth factor receptor inhibitor–associated rash, and ATR-01 for ichthyosis vulgaris, all using modified Staphylococcus epidermidis. Azitra highlights academic and technology partnerships, an IP portfolio including U.S. and foreign patents, and extensive regulatory, financing, clinical, competitive, and operational risks typical for an early-stage biotech without commercial products.
Azitra, Inc. postponed its special stockholder meeting after too few shares were represented to reach a quorum and will reconvene the meeting virtually on March 6, 2026.
Only about 13% of outstanding shares were represented, below the required 33 1/3%. Stockholders will still vote on approving the issuance of more than 19.99% of outstanding common stock under a Securities Purchase Agreement with Alumni Capital LP and on a proposal to further adjourn the meeting if needed. Shareholders who already voted and do not change their instructions do not need to act again.
Azitra, Inc. has called a virtual special stockholder meeting on February 6, 2026 to vote on issuing more than 19.99% of its outstanding common stock under NYSE American rules. The key item is approval of common shares issuable upon exercise of warrants held by Alumni Capital LP under a November 24, 2025 securities purchase agreement. Azitra has already raised about $1.5 million in gross proceeds from this private placement and could receive an additional $1.5 million in gross proceeds if the Alumni Capital warrants are exercised for cash in full, plus about $75,000 if placement agent warrants are fully exercised.
The company states that existing cash and short-term investments, including recent financings, will not fund operating and capital needs for the next twelve months. If it cannot raise additional capital in the very near term, Azitra warns it may need to delay or cut development efforts, reduce marketing, or potentially cease operations and seek protection under the United States Bankruptcy Code. Approval of the proposal would also eliminate an exchange cap limiting issuances to 19.99% and would increase dilution and potential share price volatility for current stockholders. A second proposal would allow adjournment of the meeting to solicit additional proxies if needed.